FY2025 Earnings Forecast for CRSP Issued By Leerink Partnrs

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a research note issued to investors on Monday, November 10th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($5.09) for the year, up from their prior forecast of ($5.38). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q4 2025 earnings at ($1.07) EPS, FY2026 earnings at ($5.18) EPS and FY2027 earnings at ($5.17) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $8.74 million.

Several other equities research analysts have also issued reports on the stock. Zacks Research upgraded shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Chardan Capital reiterated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, August 5th. Barclays boosted their price target on CRISPR Therapeutics from $42.00 to $56.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada lifted their price target on CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a research report on Tuesday. Eleven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $67.84.

CRISPR Therapeutics Trading Down 2.0%

NASDAQ CRSP traded down $1.06 during trading on Thursday, reaching $51.13. 391,451 shares of the company’s stock were exchanged, compared to its average volume of 2,549,014. The company’s fifty day simple moving average is $63.02 and its 200-day simple moving average is $53.44. CRISPR Therapeutics has a fifty-two week low of $30.04 and a fifty-two week high of $78.48. The firm has a market capitalization of $4.87 billion, a PE ratio of -9.17 and a beta of 1.89.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. SVB Wealth LLC purchased a new stake in CRISPR Therapeutics during the 1st quarter valued at $25,000. Costello Asset Management INC purchased a new position in shares of CRISPR Therapeutics during the first quarter valued at $27,000. Atlantic Union Bankshares Corp acquired a new stake in CRISPR Therapeutics in the second quarter valued at approximately $33,000. Thompson Investment Management Inc. acquired a new stake in CRISPR Therapeutics during the 3rd quarter worth about $33,000. Finally, Optiver Holding B.V. boosted its position in CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after purchasing an additional 210 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,895 shares of the stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the sale, the chief executive officer owned 254,201 shares of the company’s stock, valued at $17,262,789.91. This represents a 16.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 1,076 shares of the stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the transaction, the general counsel owned 83,402 shares of the company’s stock, valued at approximately $5,554,573.20. This represents a 1.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 56,213 shares of company stock worth $3,810,458 in the last ninety days. 4.30% of the stock is currently owned by insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.